Soligenix, Inc. (SNGX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Soligenix reported revenue of $0, down 100.0% from $119,371 the year before. Net income was -$11.1M, or -$2.14 per diluted share. Operating activities generated -$10.3M of cash, leaving -$10.3M of free cash flow. At fiscal year end, Soligenix held $9.2M in total assets against $3.9M in total liabilities.
Open the full interactive Soligenix financials → Quarterly statements, key ratios, valuation history and price charts.
Soligenix Key Stats
| Share Price | $0.33 |
|---|---|
| Market Cap | $5.3M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.28 – $1.72 |
| Shares Outstanding | 16.0 million (basic, 2026 Q2) |
Soligenix Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | $824,268 | $948,911 | $839,359 | $119,371 | $0 |
| Gross Profit | $538,498 | $95,628 | $398,089 | $97,311 | $0 | — |
| Operating Income | -$18.6M | -$13.1M | -$14.2M | -$7.7M | -$9.4M | -$11.8M |
| Pre-Tax Income | -$18.5M | -$13.4M | -$15.0M | -$7.9M | -$8.7M | -$11.6M |
| Income Tax | -$836,893 | -$864,742 | -$1.2M | -$1.8M | -$409,114 | -$506,615 |
| Net Income | -$17.7M | -$12.6M | -$13.8M | -$6.1M | -$8.3M | -$11.1M |
| Diluted EPS | -$153.60 | -$74.40 | -$76.96 | -$12.64 | -$4.98 | -$2.14 |
Soligenix Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.5M | -$2.6M | -$2.8M | -$2.0M |
| Diluted EPS | -$0.58 | -$0.50 | -$0.28 | -$0.12 |
Soligenix Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.7M | $26.0M | — | — | — | — |
| Current Assets | $19.5M | $26.6M | $13.9M | $9.5M | $8.8M | $8.8M |
| Total Assets | $19.9M | $26.9M | $14.3M | $9.8M | $9.0M | $9.2M |
| Current Liabilities | $6.1M | $6.3M | $16.5M | $6.2M | $4.8M | $3.7M |
| Total Long-Term Debt | $10.0M | $9.9M | $11.0M | $3.3M | $1.4M | — |
| Total Liabilities | $16.1M | $16.1M | $16.8M | $7.3M | $4.8M | $3.9M |
| Shareholders' Equity | $3.7M | $10.7M | -$2.5M | $2.5M | $4.1M | $5.3M |
Soligenix Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$11.5M | -$11.7M | -$12.6M | -$8.6M | -$8.4M | -$10.3M |
| Cash From Investing | -$7,147 | -$11,789 | -$13,073 | — | — | -$5,883 |
| Cash From Financing | $24.7M | $19.1M | $76,821 | $3.7M | $7.8M | $10.4M |
| Free Cash Flow | — | — | — | — | — | -$10.3M |
Figures from Soligenix's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Soligenix financials page for every line item.
Soligenix Company Profile
| Ticker | SNGX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000812796 |
Frequently Asked Questions
What was Soligenix's revenue in fiscal 2025?
Soligenix (SNGX) reported revenue of $0 for fiscal 2025.
What is Soligenix's annual revenue history?
Soligenix's annual revenue by fiscal year: 2020: $2.4M; 2021: $824,268; 2022: $948,911; 2023: $839,359; 2024: $119,371; 2025: $0.
What was Soligenix's net income in fiscal 2025?
Soligenix reported net income of -$11.1M for fiscal 2025.
What was Soligenix's earnings per share (EPS) in fiscal 2025?
Soligenix's diluted EPS was -$2.14 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Soligenix generate in fiscal 2025?
Soligenix generated -$10.3M of free cash flow in fiscal 2025.
What was Soligenix's revenue last quarter?
In its most recent reported quarter (2026 Q2), Soligenix reported revenue of $0.
How many shares of Soligenix are outstanding?
Soligenix reported a weighted average of 16.0 million basic shares outstanding in 2026 Q2.
What is Soligenix's market cap?
Based on its latest closing price, Soligenix (SNGX) has a market capitalization of about $5.3M.
When does Soligenix's fiscal year end?
Soligenix's fiscal year end, as registered with the SEC, is December 31.
Where is Soligenix headquartered?
Soligenix lists its business address in Princeton, New Jersey in its SEC filings.